

Implications of Recent Data Sets for the Current and Future Management of Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. In updated survival results from the Phase III DESTINY-Breast04 study evaluating trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice for HER2-low unresectable and/or metastatic breast cancer, which observation was made among patients with HR-positive disease?**

 - Overall survival (OS) and progression-free survival (PFS) were not significantly improved on the T-DXd arm
 - PFS but not OS was significantly improved on the T-DXd arm
 - PFS and OS were significantly improved on the T-DXd arm**
- 2. The antibody-drug conjugate patritumab deruxtecan targets which of the following proteins?**

 - AKT
 - HER2
 - HER3**
 - TROP2
- 3. What was the approximate reduction in risk of disease progression or death with datopotamab deruxtecan (Dato-DXd) in recently presented primary results from a Phase III study evaluating Dato-DXd versus chemotherapy for previously treated inoperable or metastatic HR-positive, HER2-negative/HER2-low breast cancer?**

 - 10%
 - 20%
 - 40%**
 - 60%
 - 80%
- 4. A prespecified event-driven OS analysis from a pivotal Phase III trial evaluating adjuvant olaparib versus placebo for patients with germline BRCA1/2 mutation-associated breast cancer reported which of the following outcomes?**

 - Inferior OS with olaparib
 - Comparable OS with olaparib and placebo
 - Improved OS with olaparib**
- 5. Updated results from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab or placebo in combination with chemotherapy followed by adjuvant pembrolizumab or placebo for localized triple-negative breast cancer showed a clinically meaningful improvement in event-free survival with the addition of (neo)adjuvant pembrolizumab for which of the following patients?**

 - Those with a pathologic complete response (pCR) after (neo)adjuvant pembrolizumab
 - Those without pCR after (neo)adjuvant pembrolizumab
 - Those with or without a pCR after (neo)adjuvant pembrolizumab**